Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye scanner software could sharpen diagnosis of macular degeneration

NCT ID NCT02827071

Diagnosis Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new software called AngioScan, used with an already-approved eye camera, to see if it can take better pictures of the back of the eye. Researchers looked at 150 patients with retinal problems like macular degeneration. The goal was to find out if the software helps doctors see and diagnose eye diseases more clearly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AngioScan angiography software (used with an FDA-approved OCT camera)
What this could lead to
If successful, this software could help doctors get clearer images of the eye, potentially leading to better diagnosis and treatment of retinal diseases.
What could go wrong
The software is not yet FDA-approved, and the study was terminated early, so results may be limited. It is a small, early-stage imaging study, not a treatment trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Start date

Jul 2016

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects with retinal vascular abnormalities

Ages

18 to 115 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • Any patient with abnormal retinal findings as determined by investigators. Exclusion Criteria: * Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging. * Participants who are unable to maintain retinal fixation on a specified target. * Participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place. * Patients with media opacity which preclude high quality imaging.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

macular degeneration retinal vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macular degeneration Retinal vascular disorder

Contacts and locations

Locations

  • Stein Eye Institute/Geffen School of Medicine

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.